ArticleBlood cell therapy2026
Persistent expression of recipient-type ABH antigen following ABO-incompatible stem cell transplantation despite complete donor-type chimerism.
Article in Blood cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Patients undergoing ABO-incompatible hematopoietic stem cell transplantation (ABOi-HSCT) demonstrate a gradual transition from their original blood group to that of the donor in the post-transplantation period. However, ABH antigens present on non-hematopoietic tissues continue to express the recipient's antigens for life. These soluble ABH antigens may adsorb from the plasma onto the donor-derived red blood cells. This phenomenon not only complicates the interpretation of the recipient's blood typing and transfusion decision after transplantation but also impacts the assessment of the patient's clinical conditions, which includes raising concerns about transplant outcomes and the potential for relapse. Herein, we report two cases of persistent weak A antigen expression in recipients following minor ABOi-HSCT, despite achieving complete donor-type chimerism. In Case 1, a 35-year-old male, AB, RhD-positive, with T-cell acute lymphoblastic leukemia (ALL), was transplanted with an HLA-matched sibling carrying the B, RhD-positive blood group. In Case 2, a 4-year-old boy, A, RhD-positive, with B-cell ALL, was transplanted with an HLA-matched related group O, RhD-positive donor. Both patients exhibited persistent antigen A in forward typing more than 18 months post-HSCT, without any sequelae. These two cases underscore the necessity of performing detailed serological investigations to accurately determine blood type following ABOi-HSCT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.